ABO blood group and von Willebrand factor: Biological implications

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 9, 2014, Pages 1273-1276

  Franchini, Massimo ^a   Crestani, Silvia ^a   Frattini, Francesco ^a   Sissa, Cinzia ^a   Bonfanti, Carlo ^a  

^a CARLO POMA HOSPITAL   (Italy)

Author keywords

ABO; ADAMTS13; Desmopressin; LRP1; Von Willebrand disease; Von Willebrand factor

Indexed keywords

VON WILLEBRAND FACTOR; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; BLOOD GROUP ABO SYSTEM;

BLOOD GROUP ABO SYSTEM; DISEASE ASSOCIATION; HEMOSTASIS; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SHORT SURVEY; THROMBOSIS; VON WILLEBRAND DISEASE; BLOOD; CHEMISTRY; GLYCOSYLATION; PHENOTYPE; PHYSIOLOGY;

ABO BLOOD-GROUP SYSTEM; ADAM PROTEINS; GLYCOSYLATION; HEMOSTASIS; HUMANS; PHENOTYPE; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 84925344154     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-0564     Document Type: Short Survey

References (37)

1. Franchini M, Liumbruno GM. ABO blood group: old dogma, new perspectives. Clin Chem Lab Med 2013;51:1545-53.
2. Storry JR, Olsson ML. The ABO blood group system revisited: a review and update. Immunohematology 2009;25:48-59.
3. Liumbruno GM, Franchini M. Beyond immunohematology: the role of the ABO blood group in human diseases. Blood Transfus 2013;11:491-9.
4. Franchini M, Favaloro EJ, Targher G, Lippi G. ABO blood group, hypercoagulability, and cardiovascular and cancer risk. Crit Rev Clin Lab Sci 2012;49:137-49.
5. Anstee DJ. The relationship between blood groups and disease. Blood 2010;115:4635-43.
6. Wu O, Bayoumi N, Vickers MA, Clark P. ABO(H) blood groups and vascular disease: a systematic review and meta-analysis. J Thromb Haemost 2008;6:62-9.
7. Dentali F, Sironi AP, Ageno W, Turato S, Bonfanti C, Frattini F, et al. Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literature. Semin Thromb Hemost 2012;38:535-48.
8. Franchini M, Makris M. Non-O blood group: an important genetic risk factor for venous thromboembolism. Blood Transfus 2013;11:164-5.
9. Dentali F, Sironi AP, Ageno W, Crestani S, Franchini M. ABO blood group and vascular disease: an update. Semin Thromb Hemost 2014;40:49-59.
10. Moeller A, Weippert-Kretschmer M, Prinz H, Kretschmer V. Influence of ABO blood groups on primary hemostasis. Transfusion 2001;41:56-60.
11. O'Donnell JS, Lasffan MA. The relationship between ABO histoblood group, factor VIII and von Willebrand factor. Transfus Med 2001;11:343-51.
12. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987;69:1691-5.
13. Jenkins PV, O'Donnell JS. ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? Transfusion 2006;46:1836-44.
14. Casari C, Lenting PJ, Wohner N, Christophe OD, Denis CV. Clearance of von Willebrand factor. J Thromb Haemost 2013;11 (Suppl 1):202-11.
15. Preston RJ, Rawley O, Gleeson EM, O'Donnell JS. Elucidating the role of carbohydrate determinants in regulating hemostasis: insights and opportunities. Blood 2013;121:3801-10.
16. Davies JA, Collins PW, Hathaway LS, Bowen DJ. von Willebrand factor: evidence for variable clearance in vivo according to Y/C1584 phenotype and ABO blood group. J Thromb Haemost 2008;6:97-103.
17. Gallinaro L, Cattini MG, Sztukowska M, Padrini R, Sartorello F, Pontara E, et al. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 2008;111:3540-5.
18. Vlot AJ, Mauser-Bunschoten EP, Zarkova AG, Haan E, Kruitwagen CL, Sixma JJ, et al. The half-life of infused factor VIII is shorter in hemophilic patients with blood group O than in those with blood group A. Thromb Haemost 2000;83:65-9.
19. Rastegarlari G, Pegon JN, Casari C, Odouard S, Navarrete AM, Saint-Lu N, et al. Macrophage LRP1 contributes to the clearance of von Willebrand factor. Blood 2012;119:2126-34.
20. Bowen DJ. An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost 2003;1:33-40.
21. O'Donnell JS, McKinnon TA, Crawley JT, Lane DA, Laffan MA. Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis. Blood 2005;106:1988-91.
22. McKinnon TA, Chion AC, Millington AJ, Lane DA, Laffan MA. N-linked glycosylation of VWF modulates its interaction with ADAMTS13. Blood 2008;111:3042-9.
23. McGrath RT, van den Biggelaar M, Byrne B, O'Sullivan JM, Rawley O, O'Kennedy R, et al. Altered glycosylation of platelet-derived von Willebrand factor confers resistance to ADAMTS13 proteolysis. Blood 2013;122:4107-10.
24. McGrath RT, McKinnon TA, Byrne B, O'Kennedy R, Terraube V, McRae E, et al. Expression of terminal alpha2-6-linked sialic acid on von Willebrand factor specifically enhances proteolysis by ADAMTS13. Blood 2010;115:2666-73.
25. McGrath RT, McRae E, Smith OP, O'Donnell JS. Platelet von Willebrand factor - structure, function and biological importance. Br J Haematol 2010;148:834-43.
26. McKinnon TA, Goode EC, Birdsey GM, Nowak AA, Chan AC, Lane DA, et al. Specific N-linked glycosylation sites modulate synthesis and secretion of von Willebrand factor. Blood 2010;116:640-8.
27. He M, Wolpin B, Rexrode K, Manson JE, Rimm E, Hu FB, et al. ABO blood group and risk of coronary heart disease in two prospective cohort studies. Arterioscler Thromb Vasc Biol 2012;32:2314-20.
28. Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995;345:152-5.
29. Reilly MP, Li M, He J, Ferguson JF, Stylianou IM, Mehta NN, et al. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet 2011;377:383-92.
30. Sramek A, Bucciarelli P, Federici AB, Mannucci PM, De Rosa V, Castaman G, et al. Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: results from a multicenter study in 47 patients. Circulation 2004;109:740-4.
31. James PD, Notley C, Hegadorn C, Leggo J, Tuttle A, Tinlin S, et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood 2007;109:145-54.
32. Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Batlle J, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007;109:112-21.
33. Castaman G, Eikenboom JC. ABO blood group also influences the von Willebrand factor (VWF) antigen level in heterozygous carriers of VWF null alleles, type 2N mutation Arg854GIn, and the missense mutation Cys2362Phe. Blood 2002;100:1927-8.
34. Davies JA, Collins PW, Hathaway LS, Bowen DJ. Effect of von Willebrand factor Y/C1584 on in vivo protein level and function and interaction with ABO blood group. Blood 2007;109:2840-6.
35. Millar CM, Riddell AF, Brown SA, Starke R, Mackie I, Bowen DJ, et al. Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations. Thromb Haemost 2008;99:916-24.
36. Castaman G, Rodeghiero F. No influence of blood group on the responsiveness to desmopressin in type I "platelet normal" von Willebrand's disease. Thromb Haemost 1995;73:551-2.
37. Castaman G, Tosetto A, Eikenboom JC, Rodeghiero F. Blood group significantly influences von Willebrand factor increase and half-life after desmopressin in von Willebrand disease Vicenza. J Thromb Haemost 2010;8:2078-80.